Prognostic Factors for Survival in Stage IIIB and IV Hodgkin's Disease: a Multivariate Analysis Comparing Two Specialist Treatment Centres

Overview

Journal Br J Cancer

Specialty Oncology

Date 1988 Oct 1

PMID 3207603

Citations 7

Authors

J Wagstaff

W M Gregory

R Swindell

D Crowther

T A Lister

Affiliations

Soon will be listed here.

Abstract

A multivariate analysis of prognostic factors was carried out on 301 patients with clinical or pathological stage III/IV Hodgkin's disease treated using the same combination chemotherapy (MVPP) at two centres (Christie Hospital, Manchester, 151 patients, St. Bartholomew's Hospital, London, 150 patients). There were no significant difference in CR or relapse free and overall survival at 5 and 10 years between the two groups. Cox analysis of the Christie data alone produced four significant factors for survival - age, sex, lymphocyte count and stage. The latter three factors showed the same trend for the St. Bartholomew's Hospital patients but failed to reach statistical significance. Analysis of the combined data showed all four factors to be of importance in predicting survival. Three different prognostic groups were identified which separated patients with good, intermediate or poor prognosis in both centres. The good prognostic group included patients aged less than 45 years, lymphocyte count greater than 0.75 x 10(9) l-1 and female patients with stage IIIB disease (5 year survival 85%). The rest were of poorer prognosis with male stage IV patients faring particularly badly (5 year survival 40%). Problems associated with the use of multivariate analysis to produce useful prognostic groupings in patients from different centres, are discussed.

Citing Articles

Simplified validated prognostic model for progression-free survival after autologous transplantation for hodgkin lymphoma.

Hahn T, McCarthy P, Carreras J, Zhang M, Lazarus H, Laport G Biol Blood Marrow Transplant. 2013; 19(12):1740-4.

PMID: 24096096 PMC: 3906436. DOI: 10.1016/j.bbmt.2013.09.018.

Current therapies in Hodgkin's disease.

Kogel K, Sweetenham J Eur J Nucl Med Mol Imaging. 2003; 30 Suppl 1:S19-27.

PMID: 12721766 DOI: 10.1007/s00259-003-1156-7.

ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial.

Hancock B, Gregory W, Cullen M, Hudson G, Burton A, Selby P Br J Cancer. 2001; 84(10):1293-300.

PMID: 11355937 PMC: 2363648. DOI: 10.1054/bjoc.2001.1778.

Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients.

Warzocha K, Bienvenu J, Ribeiro P, Moullet I, Dumontet C, Coiffier B Br J Cancer. 1998; 77(12):2357-62.

PMID: 9649158 PMC: 2150385. DOI: 10.1038/bjc.1998.391.

Prognostic factors for disease progression in advanced Hodgkin's disease: an analysis of patients aged under 60 years showing no progression in the first 6 months after starting primary chemotherapy.

Lee S, Radford J, Ryder W, Collins C, Deakin D, Crowther D Br J Cancer. 1997; 75(1):110-5.

PMID: 9000607 PMC: 2222699. DOI: 10.1038/bjc.1997.18.

References

Young R, Corder M, BERARD C, DEVITA V . Immune alterations in Hodgkin's disease. Effect of delayed hypersensitivity and lymphocyte transformation on course and survival. Arch Intern Med. 1973; 131(3):446-54. DOI: 10.1001/archinte.131.3.446. View

Longo D, Young R, Wesley M, Hubbard S, Duffey P, Jaffe E . Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol. 1986; 4(9):1295-306. DOI: 10.1200/JCO.1986.4.9.1295. View

Devita Jr V, Simon R, Hubbard S, Young R, BERARD C, Moxley 3rd J . Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med. 1980; 92(5):587-95. DOI: 10.7326/0003-4819-92-5-587. View

Rodgers R, Fuller L, Hagemeister F, Johnston D, Sullivan J, NORTH L . Reassessment of prognostic factors in stage IIIA and IIIB Hodgkin's disease treated with MOPP and radiotherapy. Cancer. 1981; 47(9):2196-203. DOI: 10.1002/1097-0142(19810501)47:9<2196::aid-cncr2820470915>3.0.co;2-1. View

SCHILLING R, McKnight B, Crowley J . Prognostic value of serum lactic dehydrogenase level in Hodgkin's disease. J Lab Clin Med. 1982; 99(3):382-7. View

Cunningham J, Mauch P, Rosenthal D, Canellos G . Long-term complications of MOPP chemotherapy in patients with Hodgkin's disease. Cancer Treat Rep. 1982; 66(4):1015-22. View

COLTMAN Jr C, Dixon D . Second malignancies complicating Hodgkin's disease: a Southwest Oncology Group 10-year followup. Cancer Treat Rep. 1982; 66(4):1023-33. View

GLICKSMAN A, Pajak T, Gottlieb A, Nissen N, Stutzman L, Cooper M . Second malignant neoplasms in patients successfully treated for Hodgkin's disease: a Cancer and Leukemia Group B study. Cancer Treat Rep. 1982; 66(4):1035-44. View

Jones S, COLTMAN Jr C, Grozea P, DePersio E, Dixon D . Conclusions from clinical trials of the Southwest Oncology Group. Cancer Treat Rep. 1982; 66(4):847-53. View

10.

Peterson B, Pajak T, Cooper M, Nissen N, Glidewell O, HOLLAND J . Effect of age on therapeutic response and survival in advanced Hodgkin's disease. Cancer Treat Rep. 1982; 66(4):889-98. View

11.

Young C, Straus D, Myers J, Passe S, Nisce L, Lee B . Multidisciplinary treatment of advanced Hodgkin's disease by an alternating chemotherapeutic regimen of MOPP/ABDV and low-dose radiation therapy restricted to originally bulky disease. Cancer Treat Rep. 1982; 66(4):907-14. View

12.

Elashoff J . Surviving proportional hazards. Hepatology. 1983; 3(6):1031-5. DOI: 10.1002/hep.1840030623. View

13.

Carde P, MacKintosh F, Rosenberg S . A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol. 1983; 1(2):146-53. DOI: 10.1200/JCO.1983.1.2.146. View

14.

Tester W, Kinsella T, Waller B, Makuch R, Kelley P, Glatstein E . Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience. J Clin Oncol. 1984; 2(7):762-9. DOI: 10.1200/JCO.1984.2.7.762. View

15.

Bakemeier R, ANDERSON J, Costello W, Rosner G, Horton J, Glick J . BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study. Ann Intern Med. 1984; 101(4):447-56. DOI: 10.7326/0003-4819-101-4-447. View

16.

Pillai G, Hagemeister F, Velasquez W, Sullivan J, Johnston D, Butler J . Prognostic factors for Stage IV Hodgkin's disease treated with MOPP, with or without bleomycin. Cancer. 1985; 55(4):691-7. DOI: 10.1002/1097-0142(19850215)55:4<691::aid-cncr2820550403>3.0.co;2-q. View

17.

Klimo P, Connors J . MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. J Clin Oncol. 1985; 3(9):1174-82. DOI: 10.1200/JCO.1985.3.9.1174. View

18.

Kant J, Hubbard S, Longo D, Simon R, Devita Jr V, Jaffe E . The pathologic and clinical heterogeneity of lymphocyte-depleted Hodgkin's disease. J Clin Oncol. 1986; 4(3):284-94. DOI: 10.1200/JCO.1986.4.3.284. View

19.

Bonadonna G, Valagussa P, Santoro A . Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. Ann Intern Med. 1986; 104(6):739-46. DOI: 10.7326/0003-4819-104-6-739. View

20.

Wagstaff J, Steward W, Jones M, Deakin D, Todd I, Wilkinson P . Factors affecting remission and survival in patients with advanced Hodgkin's disease treated with MVPP. Hematol Oncol. 1986; 4(2):135-47. DOI: 10.1002/hon.2900040206. View